Title: Repaglinide plus metformin versus metformin in treatment of type 2 diabetes: A meta-analysis
Abstract: Objective: To evaluate the efficacy and safety of repaglinide plus metformin versus metformin in patients with type 2 diabetes. Methods: Several databases were retrieved, including Pub Med, EMbase, Medline, The Cochrane Library, Wangfang, CNKI and VIP. The quality of included randomized controlled trials(RCT) was assessed according to the Cochrane Handbook 5.1.0 Collaboration System review, and then meta-analysis was performed using Rev Man 5.2. Software. Results: A total of 15 RCTs including 1031 patients met the inclusion criteria. The results of meta-analyses showed that Hb A1 c [WMD =-1.08,95%CI(-1.27,-0.90),P 0.000 01], FPG [WMD =-1.79,95%CI(-2.04,-1.54),P 0.000 01] and PPG [WMD =-2.13,95%CI(-2.60,-1.66),P 0.000 01] were significantly reduced in the repaglinide plus metformin group than that in metformin group. The risk of hypoglycemia[WMD = 3.00,95%CI(1.36,6.64),P = 0.007]is higher in repaglinide plus metformin treatment than metformin, but the risk of the gastrointestinal disorders[WMD = 0.70,95%CI(0.37,1.31),P = 0.26] were similar between the two groups. Conclusion: Repaglinide plus metformin is more effective for treatment type 2 diabetes, and is superior to the efficacy of metformin alone. The above conclusion should be verified by more large-scale high-quality studies in future.
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot